APA (7th ed.) Citation

J, L., X, S., X, H., Y, Z., Z, B., W, H., . . . L, L. (2026). A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer. Frontiers in immunology, 17, 1836220. https://doi.org/10.3389/fimmu.2026.1836220

Chicago Style (17th ed.) Citation

J, Lan, et al. "A Phase II Clinical Trial of Neoadjuvant Chemotherapy Combined with Immunotherapy and Different Radiotherapy Fractionation Regimens in HR+/HER2- Breast Cancer." Frontiers in Immunology 17 (2026): 1836220. https://doi.org/10.3389/fimmu.2026.1836220.

MLA (9th ed.) Citation

J, Lan, et al. "A Phase II Clinical Trial of Neoadjuvant Chemotherapy Combined with Immunotherapy and Different Radiotherapy Fractionation Regimens in HR+/HER2- Breast Cancer." Frontiers in Immunology, vol. 17, 2026, p. 1836220, https://doi.org/10.3389/fimmu.2026.1836220.